Dr. Leen Kawas is a distinguished biotech entrepreneur and CEO of M3 Biotechnology, a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics for neurodegenerative diseases. She is a visionary leader with a strong passion for using scientific innovation to improve the lives of patients.
Kawas began her career as a researcher, earning her Ph.D. in molecular pharmacology from Washington State University. She then went on to complete a post-doctoral fellowship in neurodegenerative diseases at the University of Washington. Her research focused on identifying new therapies for Alzheimer’s and Parkinson’s disease, which sparked her interest in biotech entrepreneurship.
In 2014, Leen Kawas founded M3 Biotechnology with the goal of developing new treatments for neurodegenerative diseases. The company’s lead product, NDX-1017, is a first-in-class small molecule that has the potential to slow or even reverse the progression of Alzheimer’s and other neurodegenerative diseases. Under Kawas’ leadership, M3 has attracted significant investment and formed strategic partnerships with leading biopharmaceutical companies.
Leen Kawas is also a passionate advocate for diversity and inclusion in the biotech industry. She has worked to create a culture of diversity and inclusion at M3, and has been recognized as a leading voice on issues related to gender and minority representation in the industry. In 2021, she was named to Fortune’s “40 under 40” list, which recognizes the most influential young leaders in business.
In addition to her work at M3, Leen Kawas is also a respected industry leader and has served on a number of advisory boards and committees. She is a member of the Washington State University Board of Regents, and serves on the advisory board for the Pacific Northwest National Laboratory. She is also a frequent speaker and commentator on issues related to biotech entrepreneurship, neurodegenerative diseases, and diversity and inclusion in the industry.
Kawas’ passion for science, dedication to patients, and commitment to diversity and inclusion make her a true inspiration and role model for aspiring biotech entrepreneurs. Her leadership and vision are helping to drive the development of innovative new therapies that have the potential to change the lives of millions of people around the world.